The present invention is directed to a method of reducing intraocular pressure.
The method comprises administering to a subject a pharmaceutical composition comprising
an effective amount of a nucleoside 5-pyrophosphate pyranoside or analogue,
which is defined by general Formula I. The method of the present invention is useful
in the treatment or prevention of ocular hypertension, such as found in glaucoma,
including primary and secondary glaucoma. The method can be used alone to reduce
intraocular pressure. The method can also be used in conjunction with another therapeutic
agent or adjunctive therapy commonly used to treat glaucoma to enhance the therapeutic
effect of reducing the intraocular pressure. The present invention also provides
a novel composition comprising a nucleoside 5-pyrophosphate pyranoside
or analogues.
